Showing results (11-20 of 269) with videos related to
Sort By:
Pageof 27
Asian Journal of Psychiatry|September 10, 2013
Suicide attempts in schizophrenic patients: clinical variablesM C Mauri, S Paletta, M Maffini, et al.Pharmacopsychiatry|November 1, 1989
Residual neuroleptic-induced parkinsonian symptoms in schizophrenia. A naturalistic study with orphenadrineA C Altamura, M C Mauri, F De Novellis, et al.Expert Opinion on Drug Safety|February 1, 2017
Paliperidone for the treatment of schizophrenia and schizoaffective disorders - a drug safety evaluationM C Mauri, A Reggiori, S Paletta, et al.Progress in Neuro-Psychopharmacology & Biological Psychiatry|May 31, 2011
Aggression and psychopharmacological treatments in major psychosis and personality disorders during hospitalisationM C Mauri, C Rovera, S Paletta, et al.EXCLI Journal|September 30, 2015
Clinical pharmacology of atypical antipsychotics: an updateM C Mauri, S Paletta, M Maffini, et al.International Clinical Psychopharmacology|January 1, 1994
Prediction of response to haloperidol in schizophrenia: neuroendocrine, neuromorphological and clinical variablesM C Mauri, A Vita, G M Giobbio, et al.Human Psychopharmacology|November 21, 2012
Safety of SSRIs during pregnancy: a controlled studyA C Altamura, I F De Gaspari, C Rovera, et al.Progress in Neuro-Psychopharmacology & Biological Psychiatry|February 1, 1996
Neurobiological and psychopharmacological basis in the therapy of bulimia and anorexiaM C Mauri, R Rudelli, E Somaschini, et al.Clinical Neuropharmacology|January 1, 1990
Drug-resistance phenomena in major psychoses: their discrimination and causal mechanismsA C AltamuraSchizophrenia Research|January 1, 1993
A multidimensional (pharmacokinetic and clinical-biological) approach to neuroleptic response in schizophrenia. With particular reference to drug resistanceA C AltamuraPageof 27